Ionis Shares Surge on Strong Financials and Clinical Breakthroughs
18.11.2025 - 09:45:05 | boerse-global.de
Ionis Pharmaceuticals is experiencing a dramatic upward trajectory, with its stock performance capturing significant market attention. The biotech firm’s impressive quarterly results and substantial pipeline advancements have converged to create powerful momentum, driven by a strategic financial decision and compelling clinical data.
Recent regulatory and clinical developments are central to the bullish sentiment. The European Union has issued a positive recommendation for the approval of DAWNZERA
, a treatment designed for hereditary angioedema. Simultaneously, the company released pivotal Phase 3 trial data for its drug candidate, Olezarsen. The results were striking, demonstrating Read more...
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
US4622221004 | IONIS | boerse | 68367620 |
